Compare

Action	Delete
Image
Title	palbociclib 帕博西尼
Price
Button	阅读更多
Excerpt	Palbociclib is an oral CDK4/6 inhibitor primarily used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It inhibits cyclin-dependent kinases 4/6 (CDK4/6), blocking cancer cell proliferation. It is often used in combination with endocrine-based therapies (such as letrozole and fulvestrant) to prolong progression-free survival. I. Mechanism of Action and Indications Palbociclib selectively inhibits CDK4/6 protein kinases, preventing cancer cells from transitioning from the G1 phase to the S phase, thereby inhibiting tumor growth. Its indications are as follows: HR+/HER2- breast cancer: Patients must be confirmed to be hormone receptor-positive and HER2-negative by testing. 1. Advanced or metastatic stage: Indicated for patients with inoperable or metastatic breast cancer. 2. Combination therapy: Typically used in combination with endocrine-based therapies (such as aromatase inhibitors) as first- or second-line treatment.
Stock status	In stock
Select all

Apply

Compare more products

Sign up to Newsletter & Follow us